Skip to main content
OpenTrials
Completed

NCT Number: NCT00896571

Transdermal Contraceptive Patch - Endometrial Effects Study

The aim of the present study is to investigate the effects of the transdermal patch on the endometrium in healthy women who require contraception.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Berlin, State of Berlin, 10629, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Requiring contraception
  • Normal cervical smear
  • Smokers not older than 30 years
  • History of regular cyclic menstrual periods

Exclusion criteria

  • Pregnancy or lactation
  • Obesity (BMI> 30 kg/m2)
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other contraceptive methods than study medication

Treatment and study plan

Ethinylestradiol/Gestogene (BAY86-5016)

Drug

7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

Primary outcomes

  1. Effect on the endometrium at cycle 13

    Time frame: 13 treatment cycles (each consisting of 28 days)

Secondary outcomes

  1. Cervical smear

    Time frame: 13 treatment cycles (each consisting of 28 days)

  2. Adverse events

    Time frame: 13 treatment cycles (each consisting of 28 days)

  3. Cycle control

    Time frame: 13 treatment cycles (each consisting of 28 days)

  4. Safety laboratory

    Time frame: 13 treatment cycles (each consisting of 28 days)

  5. Occurence of pregnancy

    Time frame: 13 treatment cycles (each consisting of 28 days)

Other outcomes

  1. Treatment compliance

    Time frame: 13 treatment cycles (each consisting of 28 days)

  2. Subjective assessment of satisfaction with the treatment

    Time frame: 13 treatment cycles (each consisting of 28 days)

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Single-center,Open-label, Uncontrolled Study to Investigate the Effects of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene on the Endometrium in a 21-day Regimen for 13 Cycles in 80 Healthy Women

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
May 11, 2009
Registry last updated
Nov 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.